Moloney Securities Asset Management LLC Sells 7,000 Shares of Intrexon Corp (NASDAQ:XON)

Moloney Securities Asset Management LLC lessened its position in shares of Intrexon Corp (NASDAQ:XON) by 36.8% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,000 shares of the biotechnology company’s stock after selling 7,000 shares during the period. Moloney Securities Asset Management LLC’s holdings in Intrexon were worth $92,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the company. First Trust Advisors LP raised its position in shares of Intrexon by 72.6% in the first quarter. First Trust Advisors LP now owns 11,227,790 shares of the biotechnology company’s stock valued at $59,058,000 after buying an additional 4,721,782 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its position in shares of Intrexon by 138.9% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,704,014 shares of the biotechnology company’s stock valued at $20,713,000 after buying an additional 1,572,077 shares in the last quarter. B. Riley Wealth Management Inc. acquired a new stake in shares of Intrexon in the first quarter valued at approximately $78,000. Finally, Steward Partners Investment Advisory LLC acquired a new stake in shares of Intrexon in the second quarter valued at approximately $58,000. Institutional investors own 77.85% of the company’s stock.

XON traded down $0.67 during trading on Friday, hitting $6.95. 2,054,562 shares of the stock traded hands, compared to its average volume of 1,095,194. Intrexon Corp has a twelve month low of $3.95 and a twelve month high of $19.94. The firm has a market cap of $1.23 billion, a P/E ratio of -5.07 and a beta of 2.22. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.57 and a current ratio of 3.91. The business’s 50 day moving average is $7.58.

Intrexon (NASDAQ:XON) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.05. Intrexon had a negative net margin of 368.47% and a negative return on equity of 29.18%. The business had revenue of $35.99 million during the quarter, compared to the consensus estimate of $29.62 million. During the same period in the previous year, the business earned ($0.51) earnings per share. The company’s revenue was down 20.6% on a year-over-year basis. On average, analysts forecast that Intrexon Corp will post -1.1 EPS for the current year.

In related news, CEO Randal J. Kirk purchased 1,257,727 shares of the stock in a transaction dated Wednesday, May 15th. The stock was bought at an average cost of $4.40 per share, for a total transaction of $5,533,998.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Randal J. Kirk purchased 376,932 shares of the stock in a transaction dated Monday, May 13th. The shares were bought at an average price of $4.25 per share, with a total value of $1,601,961.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 3,402,182 shares of company stock valued at $15,739,033 and have sold 22,672 shares valued at $173,474. 44.00% of the stock is owned by insiders.

A number of equities research analysts have recently weighed in on XON shares. ValuEngine upgraded shares of Intrexon from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Bank of America dropped their price target on shares of Intrexon from $7.00 to $6.00 and set an “underperform” rating for the company in a research report on Friday. BidaskClub downgraded shares of Intrexon from a “buy” rating to a “hold” rating in a research report on Tuesday, August 6th. Finally, Northland Securities reiterated a “hold” rating and issued a $7.00 price target on shares of Intrexon in a research report on Tuesday, May 14th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company’s stock. Intrexon has a consensus rating of “Hold” and a consensus price target of $16.25.

Intrexon Profile

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Featured Story: What are the benefits of buying treasury bonds?

Want to see what other hedge funds are holding XON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intrexon Corp (NASDAQ:XON).

Institutional Ownership by Quarter for Intrexon (NASDAQ:XON)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.